Class summary at a glance.

Every drug in the Oxaborole Antifungal class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $34.1Mcombined across class
Total Rx claims: 55K20K unique beneficiaries
Generic mfrs (active): 5across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Tavaborole

55K Part D claims (CY24) · 20K beneficiaries · First FDA approval: 2020-10-23

5 generic mfrs

Low NADAC$3.86

→

Avg plan cost$3.86

Part D spend $34.1M 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Tavaborole Topical Solution,

Brand: Tavaborole · — Part D claims (CY24) · First FDA approval: 2020-10-19

Brand-only (no generics) 5 plans require PA